CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0291185 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Ekaterina Khristenko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostical and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany. Hauptthemen laut MEDLINE: Sarcopenia, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Wasting Syndrome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Since computed tomography (CT) is a part of standard diagnostic protocol in pancreatic ductal adenocarcinoma (PDAC), we have evaluated the value of CT for sarcopenia screening in patients with PDAC, intending to expand the diagnostic value of tomographic studies. In our study, we included 177 patients with available CT images. Two groups were formed: Group 1 consisted of 117 patients with PDAC in various locations and stages and Group 2, or the control group, consisted of 60 "nominally healthy" patients with other somatic non-oncological diseases. The body mass index (BMI) was defined as a ratio of patient’s weight to the square of their height (kg/m 2 ). CT-based body composition analysis was performed using commercially available software with evaluation of sarcopenia using skeletal muscle index (SMI, cm 2 /m 2 ). Based on the SMI values, sarcopenia was found in 67.5% of patients (79 out of 117) in the first patient group. It was found more frequently in males (42 out of 56; 75%) than in females (37 out of 61; 60.6%). Additionally, we observed a decrease in muscle mass (hidden sarcopenia) in 79.7% in patients with a normal BMI. Even in overweight patients, sarcopenia was found in 50% (sarcopenic obesity). In patients with reduced BMI sarcopenia was found in all cases (100%). Statistically significant difference of SMI between two groups was revealed for both sexes (p = 0,0001), with no significant difference between groups in BMI. BMI is an inaccurate value for the assessment of body composition as it does not reflect in the details the human body structure. As SMI may correlate with the prognosis, decreased muscle mass- especially "hidden" sarcopenia or sarcopenic obesity- should be reported. The use of CT-based evaluation of sarcopenia and sarcopenic obesity will allow for a better treatment response assessment in patients with cancer cachexia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Diagnostical and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Radiology at Medical Educational and Scientific Center University Hospital, Lomonosov Moscow State University, Moscow, Russia.
- Institute for Diagnostical and Interventional Radiology, Ludwigshafen Clinical Hospital, Ludwigshafen am Rhein, Germany.
- University College Dublin School of Chemistry, Dublin, Ireland.
- Moscow City Clinical Cancer Hospital No. 1, Oncology No. 4, Moscow, Russia.
ORCID-Profile: Ekaterina Khristenko, Valentin Sinitsyn, Philipp Mayer
Zitieren
APA
Khristenko, E., Sinitsyn, V., Rieden, T., Girod, P., Kauczor, H. U., Mayer, P., Klauss, M., & Lyadov, V. (2024). CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0291185
Vancouver
Khristenko E, Sinitsyn V, Rieden T, Girod P, Kauczor HU, Mayer P, et al. CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer. PLOS ONE. 2024. doi:10.1371/journal.pone.0291185
BibTeX
@article{Khristenko2024,
author = {Khristenko, Ekaterina and Sinitsyn, Valentin and Rieden, Tatiana and Girod, Parker and Kauczor, Hans-Ulrich and Mayer, Philipp and Klauss, Miriam and Lyadov, Vladimir},
title = {CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0291185}
}
EUVIMED